药明巨诺-B(02126)倍诺达®针对二线不适合自体造血干细胞移植成人复发或难治性大B细胞淋巴瘤的新适应症上市许可申请获国家药监局受理

28 5 月, 2025

One Min Read

16 Views

Last Update: 28 5 月, 2025

Written By

Other Articles

Previous

$0.0020 Entry, $20 Target: Why BlockDAG Beats HBAR and ADA as the Best Crypto to Buy Today

Next

ST联合(600358.SH)拟增发及现金收购润田实业100%股份其主营包装饮用水业务

Related Posts

先消灭低价股！

1 Min Read

假期市场思考：A股还是美股？

1 Min Read

香港证券两日成交额破百亿！港股仍有市场？

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept